Aprea Therapeutics, Inc. (APRE) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+335.0%

$2.14

vs $0.49 price

Levered DCF

$2.23

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-10.16

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.44×	-1.4×	-1.19×	-0×	-1.65×	-1.94×	-34.92×	-18.59×
P/B	0.45×	0.94×	0.93×	0.02×	1.23×	1.34×	7.42×	-5.61×
P/S	0×	12.06×	29.15×	0×	0×	0×	0×	0×
EV / EBITDA	0.72×	0.37×	0.32×	0.76×	-0.22×	-0.29×	-28.42×	-14.36×
Gross margin	0.0%	-523.2%	98.8%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	-953.0%	-2652.8%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	-862.4%	-2449.6%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	5.63×	7.01×	5.14×	9.42×	7.73×	6.03×	14.68×	13.56×
Debt / equity	0×	0×	0×	0×	0×	0×	0×	0×
Interest coverage	0×	0×	0×	-252.73×	0×	-237.19×	-188.96×	-90,601.12×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-101.3%	-67.1%	-78.2%	-439.3%	-73.8%	-69.7%	-22.6%	30.2%
Return on invested capital	-100.5%	-69.5%	-84.7%	-420.7%	-75.3%	-67.9%	-23.7%	-27.0%
Return on assets	-79.1%	-54.0%	-63.1%	-373.6%	-64.3%	-58.1%	-21.0%	-23.5%
Free cash flow yield	-231.2%	-74.9%	-72.2%	-4560.1%	-61.7%	-40.2%	-2.9%	-5.3%
Earnings yield	-225.9%	-71.5%	-84.0%	-20540.8%	-59.8%	-51.9%	-3.0%	-5.4%
Enterprise value	-$9M	-$4.7M	-$4.6M	-$28.2M	$8.2M	$15.3M	$792.7M	$222.9M
Net debt / EBITDA	1.16×	1.77×	1.51×	0.77×	1.43×	1.67×	4.64×	4.23×
Cash conversion cycle (days)	0	-53	-86,456	-19	-2,382	-7,159	-4,667	-76,342